Grant: Project Grant
University of British Columbia
$344,025.00
Development of child-friendly oral formulations for drugs used in the maintenance therapy of childhood acute lymphoblastic leukemia
EF 2015-16
Résumé
Durable remissions in children with acute lymphoblastic leukemia (ALL) require a 2- to 3-year maintenance therapy that includes daily or weekly home administration of oral 6-mercaptopurine, methotrexate and prednisone. The current clinical practice and available drug formulations are not truly child-friendly. As a result, medication adherence is poor, leading to an increased relapse rate. This project is aimed at developing child-friendly formulations for these drugs to improve medication adherence and ultimately, the therapeutic outcome for children suffering with ALL.
Programme
Project Grant
Bénéficiaire
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
343659
Name
Li Shyh-Dar
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Project Grant Competition
Projecttitle
Development of child-friendly oral formulations for drugs used in the maintenance therapy of childhood acute lymphoblastic leukemia
Programtype2
Operating Grants
Orgnameinp2
University of British Columbia
Cihramount2
$344,025
Cihrequipment2
$0
Programname2
Project Grant
Keyworddelim
Anticancer Drug Delivery; Lipid Nanoparticles; Oral Pediatric Formulation; Oro-Dispersible Formulation
Abstract
Durable remissions in children with acute lymphoblastic leukemia (ALL) require a 2- to 3-year maintenance therapy that includes daily or weekly home administration of oral 6-mercaptopurine, methotrexate and prednisone. The current clinical practice and available drug formulations are not truly child-friendly. As a result, medication adherence is poor, leading to an increased relapse rate. This project is aimed at developing child-friendly formulations for these drugs to improve medication adherence and ultimately, the therapeutic outcome for children suffering with ALL.
Competitiondate
201603
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Li, Shyh-Dar; Rassekh, Shahrad R
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $344,025~ $0~
